MIR129-2: A Potential Drug Target and Biomarker (G406918)
MIR129-2: A Potential Drug Target and Biomarker
MIR129-2, also known as CD28 superagonist, is a cell surface protein that is expressed in a variety of tissues, including the immune system, and plays a critical role in cell-cell adhesion. It is a potential drug target and biomarker that has has been identified by researchers using various techniques, including mass spectrometry and bioinformatics analysis.
MIR129-2 is a transmembrane protein that is composed of two extracellular domains: a N-terminal cytoplasmic domain and a C-terminal transmembrane domain. The N-terminal domain contains a critical region that is involved in cell-cell adhesion, including a protein -protein interaction domain and a region that is involved in ligand binding. The C-terminal domain contains a critical region that is involved in cell-cell adhesion, including a protein-protein interaction domain and a region that is involved in ligand binding. MIR129-2 has a molecular weight of approximately 18 kDa and a calculated pI of approximately 8.0.
MIR129-2 has been shown to play a critical role in cell-cell adhesion and has been shown to be involved in various signaling pathways, including the T cell signaling pathway and the immunoglobulin (Ig) signaling pathway. MIR129-2 has also has been shown to be involved in the regulation of cell cycle progression, cell survival, and cellular processes that are important for cancer development.
Research has also shown that MIR129-2 is involved in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. MIR129-2 has also been shown to be involved in the regulation of inflammation and has been shown to play a critical role in the regulation of cellular immune responses.
Recent studies have also shown that MIR129-2 is involved in the regulation of stem cell proliferation and that it plays a critical role in the development of cancer stem cells. MIR129-2 has also been shown to be involved in the regulation of fetal development and has been shown to play a critical role in the development and maintenance of normal brain function.
Despite the importance of MIR129-2 in various signaling pathways, MIR129-2 has not yet been identified as a potential drug target. Further research is needed to determine the exact role of MIR129-2 in cell-cell adhesion and to determine its potential as a drug target.
In addition to its potential drug target potential, MIR129-2 has also been shown to be a potential biomarker for various diseases. The expression of MIR129-2 has been shown to be involved in the regulation of cellular processes that are important for disease development, including cancer, neurodegenerative diseases, and autoimmune diseases.
MIR129-2 has also been shown to be involved in the regulation of stem cell proliferation and has been shown to play a critical role in the development and maintenance of normal brain function. MIR129-2 has also been shown to be involved in the regulation of fetal development and has been shown to play a critical role in the development and maintenance of normal brain function.
In conclusion, MIR129-2 is a cell surface protein that is involved in various signaling pathways and has been shown to play a critical role in cell-cell adhesion. Its potential as a drug target and biomarker makes it an important target for further research. Further research is needed to determine the exact role of MIR129-2 in cell-cell adhesion and to determine its potential as a drug target and biomarker.
Protein Name: MicroRNA 129-2
The "MIR129-2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR129-2 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
MIR1290 | MIR1291 | MIR1292 | MIR1293 | MIR1294 | MIR1295A | MIR1295B | MIR1296 | MIR1297 | MIR1298 | MIR1299 | MIR1301 | MIR1302-1 | MIR1302-10 | MIR1302-11 | MIR1302-2 | MIR1302-3 | MIR1302-4 | MIR1302-5 | MIR1302-6 | MIR1302-7 | MIR1302-8 | MIR1302-9 | MIR1303 | MIR1304 | MIR1305 | MIR1306 | MIR1307 | MIR130A | MIR130B | MIR132 | MIR1321 | MIR1322 | MIR1323 | MIR1324 | MIR133A1 | MIR133A1HG | MIR133A2 | MIR133B | MIR134 | MIR1343 | MIR135A1 | MIR135A2 | MIR135B | MIR136 | MIR137 | MIR137HG | MIR138-1 | MIR138-2 | MIR139 | MIR140 | MIR141 | MIR142 | MIR143 | MIR144 | MIR145 | MIR1468 | MIR1469 | MIR146A | MIR146B | MIR1470 | MIR1471 | MIR147A | MIR147B | MIR148A | MIR148B | MIR149 | MIR150 | MIR151A | MIR151B | MIR152 | MIR153-1 | MIR153-2 | MIR1537 | MIR1538 | MIR1539 | MIR154 | MIR155 | MIR155HG | MIR1587 | MIR15A | MIR15B | MIR16-1 | MIR16-2 | MIR17 | MIR17HG | MIR181A1 | MIR181A1HG | MIR181A2 | MIR181A2HG | MIR181B1 | MIR181B2 | MIR181C | MIR181D | MIR182 | MIR1825 | MIR1827 | MIR183 | MIR184 | MIR185
